Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck’s (NYSE:MRK) Keytruda is its top selling drug with sales of over $7 billion in 2018. Keytruda is used for the treatment of different types of cancers, including lung, head & neck, and melanoma among others.

How Important Is Keytruda For Merck?

Merck (MRK) reported earnings 30 days ago. What's next for the stock?

Why Is Merck (MRK) Up 4.2% Since Last Earnings Report?

Merck's shares are up 11.9% this year so far on strong performance and positive regulatory updates related to its PD-1 inhibitor, Keytruda.

Here's Why Merck (MRK) is Outperforming Its Industry Of Late

Home Depot

McDonald's

Pfizer

Walgreens

Second-quarter earnings season for Dow stocks was volatile. Here's how to trade six of them now.

How To Trade Merck, Home Depot And 4 Other Dow Stocks

Merck stock is on an upswing in 2019 with a 12% gain following a 34% increase in 2018 as other pharmaceutical companies trend down. Is it time to give MRK stock a shot?

Should You Buy Pharma Giant Merck? Here's What Earnings, Merck Stock Chart Say

Twitter

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

As the Fed's path becomes murkier, two traders have some ideas on where to put money to work.

Three stocks to buy with the Fed split on rates, traders say

Coca-Cola

Microsoft

Visa

Walmart

Some members of the Dow 30 Index have offered impressive returns in the past three months and still have upside left.

Buy 5 Dow Stocks That Have Surged Despite Market Gyrations

Merck stock jumped Friday after an analyst initiated coverage of the Dow Jones pharma giant with an outperform rating, citing "the Keytruda wave." Keytruda is a blockbuster cancer drug.

How Merck Could Ride 'The Keytruda Wave' To Dominate These Rivals

Merck's (MRK) Keytruda is rapidly gaining strength as a key contributor to the company's top line. The Keytruda development program is also progressing well.

Merck's Cancer Immunotherapy Keytruda Continues to Aid Growth

EVP&Pres, Merck Animal Heallth of Merck & Co Inc (30-Year Financial, Insider Trades) Richard R.

Merck & Co Inc (MRK) EVP&Pres, Merck Animal Heallth Richard R. Deluca Sold $3.2 million of Shares

MERCK Kommanditgesellschaft auf Aktien (MKGAF) CEO Stefan Oschmann on Q2 2019 Results - Earnings Call Transcript

Novo Nordisk

Led by pharmaceuticals including Novo Nordisk and Merck KGaA MRK, +2.38% , European stocks traded higher on Thursday, with the Stoxx 600 Europe SXXP, +0.71% rising 0.8% in early action.

Europe stocks climb in early action, led by pharmas

Lockheed Martin

Raytheon

Stocks are spiraling as the U.S. and China turn the screws even tighter in their trade conflict.

Hide out in these three stocks as markets tank, investor says

AbbVie

Bristol-Myers

Johnson & Johnson

These five-star medicines should continue to push the industry higher in the next decade, despite the political blowback surrounding U.S. prescription drug prices.

These 5 Prescription Drugs Will Generate a Jaw-Dropping $62.3 Billion in 2024

Another quarter, another earnings beat for the big pharma company.

Merck Reports Fantastic Q2 Earnings Results: 4 Things You Need to Know

Merck & Co., Inc. (MRK) CEO Kenneth Frazier on Q2 2019 Results - Earnings Call Transcript

Merck (MRK) beats estimates for earnings as well as sales in second-quarter 2019. Blockbuster cancer drug, Keytruda continues its robust performance on strong demand.

Merck (MRK) Beats on Q2 Earnings & Sales, Raises '19 View

Sales of children vaccines, which includes the New Jersey-based company's MMR vaccine for measles, jumped 58% year-over-year to $675 million, Merck announced in its second-quarter earnings report.

Nasty US measles outbreak helps boost Merck's vaccine sales in second quarter

Despite political pressure to reduce drug prices, the pharma giant extended its streak of earnings beats to 22 consecutive quarters.

Merck Stock Tests Risky Level on Earnings Beat

Pharmaceutical giant Merck & Co. Inc. (NYSE:MRK) reported strong second-quarter earnings before the opening bell on Tuesday, sending shares up 3% in premarket trading.

Merck Shares Rise on Strong Sales Growth

Procter & Gamble

Stocks dropped on Tuesday morning despite some positive earnings news from high-profile companies.

Stock Market News: Procter & Gamble, Merck Can't Buoy Benchmarks

Merck & Co Inc  reported higher-than-expected second-quarter profit and revenue and raised its full-year earnings forecast on Tuesday, powered by strong demand for its blockbuster cancer immunotherapy Keytruda and vaccine sales.

Cancer drug Keytruda, vaccines propel Merck to quarterly profit beat

Merck & Co. Inc. (NYSE: MRK) released its second-quarter financial results before the markets opened on Tuesday.

Why Keytruda Made All the Difference in Merck’s Q2

Merck (MRK) delivered earnings and revenue surprises of 12.07% and 7.75%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Merck (MRK) Beats Q2 Earnings and Revenue Estimates

Merck & Co (NYSE: MRK) reported second-quarter earnings of $1.30 per share, which beat the analyst consensus estimate of $1.16 by 12.07%.

News for Merck Stock (MRK)